VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application
Time: 2022-05-07
Source: Viva Biotech
[Abstract]:VVN539 is the next clinical stage project of VivaVision after VVN001, which is expected to become a competitive ophthalmic drug globally.

VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced that it has submitted a Phase II clinical trial application for the new drug VVN539 for the treatment of open-angle glaucoma to the FDA on May 5, 2022, and will start the clinical study in June 2022.


VVN539 is a new generation, dual-targeted IOP-lowering drug that acts on the trabecular meshwork of the eye to increase the outflow of aqueous humor, thereby reducing IOP. In preclinical animal models, VVN539 has shown excellent IOP-lowering efficacy.

Media contact:
Contact Us